Nyrada Inc Achieves Key Milestone in Brain Injury Drug Trial with US Military Support

Key Highlights:

• NYR-BI03 delivers statistically significant neuroprotection in penetrating TBI model
• Collaboration with WRAIR and UNSW backs efficacy with advanced MRI imaging
• Phase I human trials underway with results due Q3 2025
• NYR shares edge up 2.67%, market cap at $20.19M

Nyrada Inc (ASX: NYR) is making waves in neurotherapeutics, announcing a breakthrough in its preclinical traumatic brain injury (TBI) study in partnership with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney. The company's lead drug candidate, NYR-BI03, demonstrated strong neuroprotective efficacy in a severe penetrating brain injury model, with MRI data confirming statistically significant protection (p = 0.043) across multiple brain regions.

The study, part of a Cooperative Research and Development Agreement (CRADA) with WRAIR, targeted military-relevant injuries using a rodent model. Over a 48-hour intravenous infusion, NYR-BI03-treated subjects showed enhanced preservation of brain tissue compared to controls. Blinded analysis by UNSW researchers further validated the results, marking a critical proof-of-concept moment for Nyrada's TRPC ion channel blocker platform.

Chair of Nyrada's Scientific Advisory Board, Professor Gary Housley, highlighted the significance of the findings, stating:
"This study provides strong evidence that NYR-BI03 protects the brain following severe TBI using a novel MRI-based quantification technique."

CEO James Bonnar echoed the optimism:

"TBI remains a major unmet clinical need, particularly within military and trauma settings. These results, in tandem with NYR-BI03’s earlier stroke efficacy, position it as a promising first-in-class treatment option."

The preclinical win supports the company’s ongoing Phase I clinical trial, which commenced in March and is evaluating NYR-BI03’s safety and tolerability in humans. Final results are expected in Q3 2025, with the trial registered with the US National Institutes of Health and executed through Scientia Clinical Research.

Adding further momentum, Nyrada filed a provisional patent in late 2024 to protect its TRPC-targeting drug structures. A preliminary international patent search confirmed the novelty of its approach, enhancing its IP moat in a highly competitive biopharma space.

Stock Snapshot

Nyrada's share price ticked up 2.67% to $0.096 on the back of today’s announcement. The stock has traded between $0.032 and $0.155 over the past year and remains down 20% on a 12-month basis. With 210.33 million shares on issue and a market cap of $20.19 million, the company ranks 1,464 out of 2,324 on the ASX.

Despite broader ASX healthcare sector weakness, Nyrada’s progress stands out as a rare bright spot—especially as geopolitical uncertainty continues to weigh on risk appetite across global markets.

As the Phase I trial progresses, investor attention will likely shift to upcoming clinical readouts. With no approved drug treatment for TBI currently on the market, the stakes—and potential upside—could be substantial.